Vincenzo Guiducci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2793774/publications.pdf

Version: 2024-02-01

40 papers

1,500 citations

430754 18 h-index 315616 38 g-index

44 all docs 44 docs citations

44 times ranked 2362 citing authors

#	Article	IF	CITATIONS
1	Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet, The, 2018, 392, 835-848.	6.3	215
2	No Evidence of Association Between Prothrombotic Gene Polymorphisms and the Development of Acute Myocardial Infarction at a Young Age. Circulation, 2003, 107, 1117-1122.	1.6	191
3	Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI. Journal of the American College of Cardiology, 2020, 76, 2321-2330.	1.2	154
4	Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management. Journal of the American College of Cardiology, 2017, 69, 2592-2603.	1.2	132
5	Results and complications of the carotid sinus massage performed according to the "method of symptoms― American Journal of Cardiology, 2002, 89, 599-601.	0.7	123
6	Two-Year Clinical Outcomes With Drug-Eluting Stents for Diabetic Patients With De Novo Coronary Lesions. Circulation, 2008, 117, 923-930.	1.6	66
7	Timing of Oral P2Y12 Inhibitor Administration in Patients With Non-ST-Segment Elevation AcuteACoronary Syndrome. Journal of the American College of Cardiology, 2020, 76, 2450-2459.	1.2	64
8	Complete revascularization reduces cardiovascular death in patients with ST-segment elevation myocardial infarction and multivessel disease: systematic review and meta-analysis of randomized clinical trials. European Heart Journal, 2020, 41, 4103-4110.	1.0	59
9	Clinical impact of an inter-hospital transfer strategy in patients with ST-elevation myocardial infarction undergoing primary angioplasty: the Emilia-Romagna ST-segment elevation acute myocardial infarction network. European Heart Journal, 2008, 29, 1834-1842.	1.0	56
10	Comparison of sirolimus-eluting and bare metal stent for treatment of patients with total coronary occlusions: results of the GISSOC II-GISE multicentre randomized trial. European Heart Journal, 2010, 31, 2014-2020.	1.0	56
11	Design and rationale for the Minimizing Adverse haemorrhagic events by TRansradial access site and systemic Implementation of angioX program. American Heart Journal, 2014, 168, 838-845.e6.	1.2	47
12	Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trial. European Heart Journal, 2008, 29, 2972-2980.	1.0	41
13	Risk of Adverse Cardiac and Bleeding Events Following Cardiac and Noncardiac Surgery in Patients With Coronary Stent. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 39-47.	0.9	40
14	Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI). American Heart Journal, 2004, 148, 378-385.	1.2	37
15	Impact of COVID-19 pandemic and diabetes on mechanical reperfusion in patients with STEMI: insights from the ISACS STEMI COVID 19 Registry. Cardiovascular Diabetology, 2020, 19, 215.	2.7	30
16	Impact of SARS-CoV-2 positivity on clinical outcome among STEMI patients undergoing mechanical reperfusion: Insights from the ISACS STEMI COVID 19 registry. Atherosclerosis, 2021, 332, 48-54.	0.4	28
17	COVID-19 pandemic, mechanical reperfusion and 30-day mortality in ST elevation myocardial infarction. Heart, 2022, 108, 458-466.	1.2	28
18	Physiology-guided revascularization versus optimal medical therapy of nonculprit lesions in elderly patients with myocardial infarction: Rationale and design of the FIRE trial. American Heart Journal, 2020, 229, 100-109.	1.2	24

#	Article	IF	Citations
19	Safety and Long-Term Efficacy of Sirolimus Eluting Stent in ST-elevation Acute Myocardial Infarction: The REAL (Registro REgionale AngiopLastiche Emilia-Romagna) Registry. Cardiovascular Drugs and Therapy, 2006, 20, 63-68.	1.3	16
20	Incidence and Outcome of High On-Treatment Platelet Reactivity in Patients With Non-ST Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the VIP) Tj ETQq0 0 0 rgBT	/Overlock :	10 Tf 50 702 ⁻
21	792-798. Same-day transfer for the invasive strategy of patients with non-ST-segment elevation acute coronary syndrome admitted to spoke hospitals: Data from the Emilia-Romagna Regional Network. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 428-434.	0.4	10
22	Kidney dysfunction and short term all-cause mortality after transcatheter aortic valve implantation. European Journal of Internal Medicine, 2020, 81, 32-37.	1.0	9
23	Left Ventricular Function After ST-Elevation Myocardial Infarction in Patients Treated With Primary Percutaneous Coronary Intervention and Abciximab or Tirofiban (from the Facilitated Angioplasty) Tj ETQq1 1 C).78 ⊕ 3714 r _j	gBT&Overlock
24	Coronary stenting using the radial approach in two women with situs viscerum inversus and acute myocardial infarction. Cardiovascular Revascularization Medicine, 2012, 13, 128-132.	0.3	8
25	Comparison of longâ€term clinical outcomes in multivessel coronary artery disease patients treated either with bioresoarbable polymer sirolimusâ€eluting stent or permanent polymer everolimusâ€eluting stent: 5â€year results of the CENTURY II randomized clinical trial. Catheterization and Cardiovascular Interventions, 2020, 95, 175-184.	0.7	8
26	Impact of body mass index on the outcome of elderly patients treated with transcatheter aortic valve implantation. Internal and Emergency Medicine, 2022, 17, 369-376.	1.0	6
27	Red blood cell distribution width in patients undergoing transcatheter aortic valve implantation: Implications for outcomes. International Journal of Clinical Practice, 2021, 75, e14153.	0.8	4
28	Balloon aortic valvuloplasty as a palliative treatment in patients with severe aortic stenosis and limited life expectancy: a single center experience. Aging, 2020, 12, 16597-16608.	1.4	4
29	Complete versus culpritâ€only strategy in older MI patients with multivessel disease. Catheterization and Cardiovascular Interventions, 2022, 99, 970-978.	0.7	4
30	Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion: Insight from an international STEMI registry. Biomedicine and Pharmacotherapy, 2021, 138, 111469.	2.5	3
31	Search for familial hypercholesterolemia patients in an Italian community: A real-life retrospective study. Nutrition, Metabolism and Cardiovascular Diseases, 2022, , .	1.1	3
32	Acute myocardial infarction due to spontaneous coronary artery dissection treated with primary coronary angioplasty: a case report. Journal of Cardiovascular Medicine, 2007, 8, 738-740.	0.6	2
33	Time to treatment and ST-segment resolution in high-risk patients with acute myocardial infarction transferred from community hospitals for coronary angioplasty after pharmacological treatment. Journal of Cardiovascular Medicine, 2008, 9, 32-38.	0.6	2
34	Complete Revascularization in Patients Undergoing a Pharmacoinvasive Strategy for ST-Segment–Elevation Myocardial Infarction: Insights From the COMPLETE Trial. Circulation: Cardiovascular Interventions, 2021, 14, e010458.	1.4	2
35	Impact of sex on comparative outcomes of bivalirudin versus unfractionated heparin in patients with acute coronary syndromes undergoing invasive management: a pre-specified analysis of the MATRIX trial. EuroIntervention, 2019, 15, e269-e278.	1.4	2
36	Economic appraisal of the angioplasty procedures performed in 2004 in a high-volume diagnostic and interventional cardiology unit. Journal of Cardiovascular Medicine, 2007, 8, 792-798.	0.6	1

#	Article	IF	CITATIONS
37	Downstream or upstream administration of P2Y12 receptor blockers in non-ST elevated acute coronary syndromes: study protocol for a randomized controlled trial. Trials, 2020, 21, 966.	0.7	1
38	Renin-Angiotensin System inhibitors and mortality among diabetic patients with STEMI undergoing mechanical reperfusion during the COVID Pandemic. Diabetes Epidemiology and Management, 2021, 4, 100022.	0.4	1
39	Angiographic control versus ischaemia-driven management of patients undergoing percutaneous revascularisation of the unprotected left main coronary artery with second-generation drug-eluting stents: rationale and design of the PULSE trial. Open Heart, 2020, 7, e001253.	0.9	1
40	Response to Letters Regarding Article, "Two-Year Clinical Outcomes With Drug-Eluting Stents for Diabetic Patients With De Novo Coronary Lesions: Results From a Real-World Multicenter Registry― Circulation, 2008, 118, .	1.6	0